January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January ...

The stock value and growth potential of a biotech firm depend on the type of diseases it treats. This might also include the research that the firm does as it supports other companies, diseases or ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

But local biotech leaders see signs of change in 2025 ... Ubaghs Carrión sees a few trends in the types of deals being made. For one, he said most of the deals (including IDRx and Scorpion ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...